Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer
Recruiting · NCT07226115 · Observational (researchers observe without assigning treatment) · Lead sponsor: City of Hope Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Colorectal cancer (CRC) remains one of the leading causes of cancer-related mortality worldwide. Although adjuvant chemotherapy improves survival after curative resection, its efficacy varies widely among patients. The absence of reliable predictive biomarkers often leads to overtreatment or undertreatment. This study aims to develop a machine learning-based predictive model for adjuvant chemotherapy response using tumor-derived alternative splicing signatures. By integrating RNA-seq data, splicing isoform and clinical outcomes, this study seeks to identify molecular predictors of treatment response and recurrence risk after surgery.
Who can take part
Inclusion criteria
- Histologically confirmed stage II-III colorectal cancer (TNM classification, 8th edition)
- Received standard adjuvant chemotherapy after curative resection
- Availability of tumor tissue (FFPE or frozen) before chemotherapy
- Sufficient clinical data for outcome analysis (recurrence, survival)
- Age 18-80 years Stage
Exclusion criteria
- Inflammatory bowel disease
- Inadequate RNA quality or lack of consent
Where it is running
1 location listed across 1 US state.
- City of Hope Medical Center - Duarte, California, United States